如果最高法院裁定特朗普政府的部分关税为非法，美国财政部可能将不得不退还"大约一半的关税"。一个围绕关税裁决的金融投机交易市场已经形成， 对冲基金以每1美元索赔权20至40美分的价格，从现金流紧张的进口商手中购买未来可能获得关税退款的索赔权，而个人投资者则通过Kalshi和 Polymarket等新兴的预测市场参与这场博弈。 美国财政部长贝森特近日在接受媒体采访时公开承认， 如果最高法院裁定特朗普政府的部分关税为非法，美国财政部可能将不得不退还"大约一半的关 税"，他将此形容为对财政部的"可怕"打击。 当被问及政府是否准备好退款时，贝森特回应称："如果法院这么说，我们就必须这么做。" 这一表态的背景，是两家下级法院已裁定特朗普政府援引《国际紧急经济权力法》征收部分关税缺乏法律授权。目前，此案已上诉至最高法院，定于11 月5日举行口头辩论。 据美国海关与边境保护局数据，截至今年8月，争议关税已征收超过700亿美元，而如果裁决最终推翻该政策，其引发的连锁反应将对美国财政和进口 企业产生深远影响。 面对巨大的不确定性，市场并未等待。 从华尔街投行的结构化产品到线上预测平台，一个围绕关税裁决结果的"定价"机制已然形成。 ...

华尔街的投资银行正在构建一个特殊的"金融赌局"。据报道，对冲基金以每1美元索赔权20至40美分的价格，从现金流紧张的进口商手中购买未来可能获 得关税退款的索赔权。 10月25日，据媒体援引知情人士透露，Jefferies和Oppenheimer等公司正在积极撮合此类交易。它们将支付了高额关税的进口商与寻求投资机会的投 资者（主要是对冲基金）进行匹配。 这些交易的核心逻辑在于， 投资者以远低于潜在退款金额的价格购入索赔权 。 据报道，投资银行一直在接触美国多个州的海关报关行，寻求从现金流紧张的进口商手中购买索赔权。 一份Oppenheimer的推介材料写道： 该解决方案提供了一种能力，可以消除结果的不确定性，并立即获得有保证的付款，而无需等待法院的最终裁决。 据媒体援引相关信函及匿名知情人士透露， 对冲基金可能以每1美元索赔权20至40美分的价格买入，这意味着一旦赌赢，他们将获得数倍于原始投资的 回报 。 据一位知情人士称，大多数交易的规模在200万至2000万美元之间，极少超过1亿美元的交易。 该公司在材料中称， 其特殊资产团队自2021年以来，已围绕早于特朗普最新一轮关税的美中关税，安排了超过16亿美元的类 ...

华尔街的投资银行正在构建一个特殊的"金融赌局"，押注美国最高法院将最终裁定特朗普政府时期的部分关税为非法，从而迫使美国政府向进口商支付巨额退 税。 10月25日，据媒体援引知情人士透露，Jefferies和Oppenheimer等公司正在积极撮合此类交易。它们将支付了高额关税的进口商与寻求投资机会的投资者（主 要是对冲基金）进行匹配。 在这些交易中，进口商实质上是将其未来可能获得的关税退款索赔权，以折扣价出售给投资者 。 如果最高法院最终做出有利于挑战关税一方的裁决，投资者将获得索赔权面值与购买价之间的巨额差价，而负责安排交易的银行则从中抽取佣金。 低价买入退税权，对赌高额回报 这些交易的核心逻辑在于， 投资者以远低于潜在退款金额的价格购入索赔权 。 据报道，投资银行一直在接触美国多个州的海关报关行，寻求从现金流紧张的进口商手中购买索赔权。 一份Oppenheimer的推介材料写道： 该解决方案提供了一种能力，可以消除结果的不确定性，并立即获得有保证的付款，而无需等待法院的最终裁决。 该公司在材料中称， 其特殊资产团队自2021年以来，已围绕早于特朗普最新一轮关税的美中关税，安排了超过16亿美元的类似交易 。 ...

Core Viewpoint - Investment banks on Wall Street are creating a unique "financial gamble" by betting that the U.S. Supreme Court will eventually rule certain tariffs imposed during the Trump administration as illegal, potentially forcing the U.S. government to pay back significant refunds to importers [1][4]. Group 1: Investment Strategy - Firms like Jefferies and Oppenheimer are actively facilitating transactions that match importers who have paid high tariffs with investors, primarily hedge funds, seeking investment opportunities [1][2]. - Importers are effectively selling their future potential claims for tariff refunds at a discounted price to investors, allowing for significant profit margins if the Supreme Court rules in favor of the challengers [2][3]. - The core logic of these transactions is that investors can purchase claims at a fraction of the potential refund amount, with hedge funds reportedly buying claims for 20 to 40 cents on the dollar, indicating potential returns several times the original investment [3]. Group 2: Transaction Details - Most transactions are sized between $2 million and $20 million, with very few exceeding $100 million [3]. - Since 2021, Oppenheimer's special asset team has arranged over $1.6 billion in similar transactions related to tariffs prior to the latest round imposed by Trump [3]. Group 3: Legal Context - The outcome of this financial gamble hinges on the Supreme Court's decision, which is set to hear arguments on November 5 regarding the legality of tariffs imposed under the International Economic Emergency Powers Act [4]. - If the Supreme Court rules that the tariffs are illegal, the U.S. government may be required to refund a substantial portion of the collected tariffs, with net customs revenue from increased tariffs projected to reach $195 billion by fiscal year 2025 [5]. Group 4: Refund Process Challenges - Even if the Supreme Court overturns the tariffs, the refund process is expected to be complex, particularly for importers using commercial couriers like FedEx and United Parcel, as refunds are only issued to registered importers and may require documentation for each shipment [6].

Group 1 - RBC Capital Markets initiates coverage on AppLovin with an "Outperform" rating and a target price of $700 [1] - Analysts highlight the increasing importance of Return on Ad Spend (ROAS) and attribution analysis, leading to a faster integration of advertising technology and marketing technology [1] - AppLovin's platform is expanding its reach with diversified demand sources, benefiting from personalized marketing and e-commerce retail media trends, indicating long-term growth potential [1] Group 2 - Analysts expect AppLovin's fixed cost model to achieve significant growth in 2026, maintaining industry-leading profit margins [1] - Following a recent advisory call, Wedbush raised its target price for AppLovin from $725 to $745 [1] - Oppenheimer notes that potential SEC investigation into AppLovin's data collection processes is not expected to have a substantial impact [2]

Core Insights - The company Oppenheimer (NYSE: OPY) reported a strong quarter, benefiting from a quick recovery in markets which supported its wealth management business, leading to record assets under management (AUM) [2] - The volatility in prior markets positively impacted the sales and trading activities of the company, indicating a favorable environment for these operations [2] - The Value Lab, an investment group associated with Oppenheimer, focuses on long-only value investment strategies, aiming for a portfolio yield of approximately 4% [1][2] Group 1 - Oppenheimer's wealth management business achieved fresh records in AUM due to market recovery [2] - The sales and trading activities experienced a positive outcome due to previous market volatility [2] - The Value Lab offers members real-time updates, global market news, and feedback on stock ideas, enhancing investor engagement [2] Group 2 - The Valkyrie Trading Society consists of analysts who focus on high conviction, non-correlated investment ideas in developed markets, aiming for limited downside risk and outsized returns [3]

Core Insights - Oppenheimer (NYSE: OPY) reported a strong quarter, benefiting from a quick market recovery that supported its wealth management business, leading to record assets under management (AUM) [2] - The volatility in prior markets positively impacted sales and trading activities, contributing to the overall performance of the company [2] - The Value Lab, an investment group, focuses on long-only value ideas, aiming for a portfolio yield of approximately 4% and has seen success over the past five years by engaging in international markets [1] Group 1 - Oppenheimer's wealth management business achieved fresh records in AUM due to market recovery [2] - The sales and trading activities thrived as a result of previous market volatility [2] - The Value Lab offers members real-time updates, global market news, and feedback on stock ideas, enhancing investment strategies [2] Group 2 - The Valkyrie Trading Society consists of analysts sharing high-conviction, non-correlated investment ideas aimed at generating outsized returns in the current economic climate [3] - The society focuses on long-only investments, indicating a conservative approach to risk management [3]

Core Insights - Oppenheimer & Co. Inc. has appointed James Yoo as Managing Director in its Healthcare Equity Capital Markets Investment Banking Group, focusing on Biotechnology Equity Capital Markets transactions [1][3] Group 1: Appointment and Role - James Yoo brings 27 years of experience and expertise in various financing structures, including PIPEs, Follow-on Offerings, CMPOs, and Registered Direct transactions [2] - His previous role involved advising healthcare-dedicated investment funds and biotechnology companies on Oppenheimer's Sales & Trading Desk since 2023 [3] Group 2: Impact on the Company - Yoo's track record and relationships in the biotechnology investment community are expected to enhance Oppenheimer's leadership in Healthcare Equity Capital Markets [3] - The firm aims to provide innovative capital markets solutions to help biotech companies secure necessary financing for advancing science and improving patient outcomes [4]

Core Viewpoint - Nike has shown a significant improvement in revenue, indicating a potential reinvigoration under new management, despite ongoing challenges in the competitive landscape and macroeconomic conditions [2][4][5]. Revenue Performance - Nike's recent quarter reported a revenue beat, with sales showing improvement compared to previous periods, although still not meeting the company's historical standards [2][4]. - Gross margins were better than expected, and the company effectively controlled expenses, contributing to the positive revenue performance [2]. Management and Strategy - Under new management, Nike is focusing on product innovation and re-engaging with wholesale partners, which is expected to take time but may lead to further progress in the coming quarters [4][5]. - The narrative suggests that Nike is on a path to reinvigorate its brand and operations, which could enhance its market position [4]. Competitive Landscape - There are concerns that Nike has lost its competitive edge, allowing rivals to gain market share, compounded by a challenging macroeconomic environment and uncertainties in China [5][6]. - The competitive landscape is described as increasingly difficult, with potential impacts from tariffs and consumer behavior in China [5][6]. Importance of China Market - Currently, China represents a relatively small market for Nike, but its significance may grow if the company successfully reinvigorates its business and attracts higher investor interest [7]. - As long as the situation in China does not deteriorate significantly, improvements in other areas of Nike's business could be sufficient for the company's overall performance [8].

Core Insights - Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is identified as a promising investment opportunity, particularly after Goldman Sachs increased its stake by 93.6% [1] - Oppenheimer has issued an 'Outperform' rating for Olema Pharmaceuticals following its collaboration with Pfizer, setting a price target of $22, indicating significant growth potential [2] - The company is strategically positioned in the HR-positive breast cancer market, with ongoing studies involving its drug palazestrant and Novartis's ribociclib, suggesting a potential upside of over 130% [3] Company Overview - Olema Pharmaceuticals, Inc. is a California-based clinical-stage biopharmaceutical company focused on developing therapies for women's cancers, particularly breast cancer [4]